Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 | P41145 | 7/20 | 0.44 |
| ▸ | ABL1 | P00519 | 7/20 | 0.42 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | ACACB | O00763 | 1/20 | 0.39 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.39 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.39 |
| ▸ | JAK2 | O60674 | 1/20 | 0.39 |
| ▸ | JAK1 | P23458 | 1/20 | 0.39 |
| ▸ | TYK2 | P29597 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31121722 | 1.00 | OPRK1 (0.44) | OPRK1ABL1P2RY12POLBACACB | |
| SCHEMBL24214266 | 0.87 | OPRK1 (0.53) | OPRK1ABL1P2RY12 | |
| SCHEMBL25933701 | 0.84 | OPRK1 (0.41) | OPRK1ABL1P2RY12POLBNR1H2 | |
| SCHEMBL4131161 | 0.83 | OPRK1 (0.51) | OPRK1P2RY12 | |
| SCHEMBL19689497 | 0.82 | OPRK1 (0.42) | OPRK1P2RY12POLBNR1H2NR1H3 | |
| SCHEMBL29779599 | 0.81 | P2RY12 (0.47) | OPRK1ABL1P2RY12 | |
| SCHEMBL23166436 | 0.81 | P2RY12 (0.47) | OPRK1ABL1P2RY12 | |
| SCHEMBL24215693 | 0.79 | OPRK1 (0.45) | OPRK1P2RY12 | |
| SCHEMBL23167377 | 0.79 | P2RY12 (0.46) | OPRK1P2RY12POLB | |
| SCHEMBL24215455 | 0.79 | OPRK1 (0.45) | OPRK1ABL1P2RY12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260055094-A1 | FXR (NR1H4) MODULATING COMPOUNDS | GILEAD SCIENCES INC (US) | 2026-02-26 | — | — | US | disclosed |
| US-12358903-B2 | FXR (NR1H4) modulating compounds | GILEAD SCIENCES, INC. (US) | 2025-07-15 | — | — | US | disclosed |
| EP-4534536-A1 | FXR (NR1H4) MODULATING COMPOUNDS | Gilead Sciences, Inc. (US) | 2025-04-09 | — | — | EP | disclosed |
| EP-4089072-B1 | FXR (NR1H4) MODULATING COMPOUNDS | GILEAD SCIENCES INC (US) | 2024-08-28 | — | — | EP | disclosed |
| CN-117924266-A | Compounds that modulate FXR (NR 1H 4) | 吉利德科学公司 | 2024-04-26 | — | — | CN | disclosed |
| CN-117924267-A | Compounds that modulate FXR (NR 1H 4) | 吉利德科学公司 | 2024-04-26 | — | — | CN | disclosed |
| CN-109476636-B | Compounds that modulate FXR (NR 1H 4) | 吉利德科学公司 | 2024-01-09 | — | — | CN | disclosed |
| US-11739065-B2 | FXR (NR1H4) modulating compounds | GILEAD SCIENCES, INC. (US) | 2023-08-29 | — | — | US | disclosed |
| US-11739065-B2 | FXR (NR1H4) modulating compounds | GILEAD SCIENCES, INC. (US) | 2023-08-29 | — | — | US | disclosed |
| US-11739065-B2 | FXR (NR1H4) modulating compounds | GILEAD SCIENCES, INC. (US) | 2023-08-29 | — | — | US | disclosed |
| US-10329286-B2 | FXR (NR1H4) modulating compounds | GILEAD SCIENCES, INC. (US) | 2019-06-25 | — | — | US | disclosed |
| WO-2017218337-A1 | FXR (NR1H4) MODULATING COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2017-12-21 | — | — | WO | disclosed |
| WO-2017218330-A1 | FXR (NR1H4) MODULATING COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2017-12-21 | — | — | WO | disclosed |
| EP-3257847-A1 | FXR (NR1H4) MODULATING COMPOUNDS | Gilead Sciences, Inc. (US) | 2017-12-20 | — | — | EP | disclosed |
| EP-3257847-A1 | FXR (NR1H4) MODULATING COMPOUNDS | Gilead Sciences, Inc. (US) | 2017-12-20 | — | — | EP | disclosed |
| US-20170355685-A1 | FXR (NR1H4) MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2017-12-14 | — | — | US | disclosed |
| US-20170355685-A1 | FXR (NR1H4) MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2017-12-14 | — | — | US | disclosed |
| US-20170355685-A1 | FXR (NR1H4) MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2017-12-14 | — | — | US | disclosed |
| US-20170355693-A1 | FXR (NR1H4) MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2017-12-14 | — | — | US | disclosed |
| US-20170355693-A1 | FXR (NR1H4) MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2017-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12358903-B2 | FXR (NR1H4) modulating compounds | NR1H4, NR1H2, NR1H3 | OPRK1 662/4885ABL1 2990/4885P2RY12 1326/4885 |
| US-10329286-B2 | FXR (NR1H4) modulating compounds | NR1H4, NR1H2, NR1H3 | OPRK1 662/4885ABL1 2990/4885P2RY12 1326/4885 |
| US-11739065-B2 | FXR (NR1H4) modulating compounds | NR1H4, NR1H2, NR1H3 | OPRK1 662/4885ABL1 2990/4885P2RY12 1326/4885 |
| US-20170355685-A1 | FXR (NR1H4) MODULATING COMPOUNDS | NR1H4, NR1H2, NR1H3 | OPRK1 662/4885ABL1 2990/4885P2RY12 1326/4885 |
| US-20260055094-A1 | FXR (NR1H4) MODULATING COMPOUNDS | NR1H4, NR1H2, NR1H3 | OPRK1 282/4885ABL1 2221/4885P2RY12 1561/4885 |
| US-20170355693-A1 | FXR (NR1H4) MODULATING COMPOUNDS | NR1H4, NR1H2, NR1H3 | OPRK1 662/4885ABL1 2990/4885P2RY12 1326/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.